NCT Number: NCT06105918
Phase: PHASE1
Trial Summary: This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 [177Lu-rhPSMA-10.1]) after prostate specific membrane antigen (PSMA) positron emissi- clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s):
Acronym:
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives